Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Caleb Whitenack

Psychiatry Durham, NC Medical Doctor

NPI 1770872160 CMS profile 1364643

5501 Fortunes Ridge Dr Ste P, Durham, NC 27713

Open in the dashboard

General payments

$68,048

410 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caleb Whitenack of Durham, NC is reported in the CMS Open Payments database as having received $68,048 across 410 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,418 12
2024 General $16,852 22
2023 General $32,384 81
2022 General $1,331 84
2021 General $4,208 50
2020 General $2,937 62
2019 General $1,918 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caleb Whitenack
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Caleb Whitenack were reported at $8,418. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Caleb Whitenack Psychiatry median Middle half National median
2019 $1,918 $184 $59–$605 $163
2020 $2,937 $119 $36–$372 $114
2021 $4,208 $143 $43–$576 $132
2022 $1,331 $153 $50–$590 $149
2023 $32,384 $170 $56–$651 $160
2024 $16,852 $179 $57–$673 $164
2025 $8,418 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axsome Therapeutics, Inc. $55,232 72 payments
  2. Allergan Inc. $3,759 26 payments
  3. AbbVie, Inc. $2,746 55 payments
  4. Neuronetics, Inc. $1,601 4 payments
  5. Sunovion Pharmaceuticals Inc. $587 39 payments
  6. Otsuka America Pharmaceutical, Inc. $537 33 payments
  7. Teva Pharmaceuticals USA, Inc. $428 24 payments
  8. Lundbeck LLC $390 18 payments
  9. Janssen Pharmaceuticals, Inc $312 10 payments
  10. ITI, Inc. $292 16 payments
  11. Other $2,164 113 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $43,200 25 payments
  2. Food and Beverage $8,496 362 payments
  3. Honoraria $7,225 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,400 6 payments
  5. Travel and Lodging $3,507 13 payments
  6. Education $220 3 payments
Products named General payments · program years 2019–2025
  1. Auvelity $55,184 70 payments
  2. VRAYLAR Neuroscience $4,046 56 payments
  3. VRAYLAR Neuroscience $2,455 24 payments
  4. Neurostar TMS Therapy System $1,478 2 payments
  5. LATUDA $587 39 payments
  6. SPRAVATO $312 10 payments
  7. CAPLYTA $292 16 payments
  8. APLENZIN $269 13 payments
  9. ABILIFY MAINTENA $244 14 payments
  10. AUSTEDO $209 19 payments
  11. Other $3,822 200 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

250

Median for Psychiatry: 574

Drug cost

$5,766

Median for Psychiatry: $27,624

Branded share of claims

30.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lamotrigine Er Lamotrigine Brand 11 $2,050
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 23 $576
Lurasidone Hcl Generic 12 $476
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 15 $377
Gabapentin Generic 17 $357
Lamotrigine Generic 23 $348
Clonazepam Generic 24 $316
Bupropion Xl Bupropion Hcl Brand 15 $233
Buspirone Hcl Generic 11 $215
Aripiprazole Generic 18 $182

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$12,265

Medicare's payments for the services billed

Medicare patients

12

Average age 66

Services billed

143

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Chronic kidney disease 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $16,852
$16,852 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

410 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record